Recently Expired Drugs

1. Acetadote patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8653061 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(15 days ago)

US8399445 CUMBERLAND PHARMS Acetylcysteine composition and uses thereof
Aug, 2025

(15 days ago)




Drugs and Companies using ACETYLCYSTEINE ingredient

Market Authorisation Date: 23 January, 2004

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: INJECTABLE

How can I launch a generic of ACETADOTE before it's drug patent expiration?
More Information on Dosage

ACETADOTE family patents

Family Patents

2. Amitiza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748481 SUCAMPO PHARMA LLC Method for treating gastrointestinal disorder
Sep, 2025

(7 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-670) Apr 19, 2016
M(M-225) Apr 26, 2021

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 29 April, 2008

Treatment: Method for the long term treatment of chronic constipation in a human subject with irritable bowel syndrome

Dosage: CAPSULE

How can I launch a generic of AMITIZA before it's drug patent expiration?
More Information on Dosage

AMITIZA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Duzallo patent expiration

Can you believe DUZALLO received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(14 days ago)




Drugs and Companies using ALLOPURINOL; LESINURAD ingredient

Market Authorisation Date: 18 August, 2017

Treatment: NA

Dosage: TABLET

More Information on Dosage

DUZALLO family patents

Family Patents

4. Erivedge patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9790183 GENENTECH Pyridyl inhibitors of hedgehog signalling
Sep, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 30, 2017

Drugs and Companies using VISMODEGIB ingredient

NCE-1 date: 31 January, 2016

Market Authorisation Date: 30 January, 2012

Treatment: Method of using vismodegib to treat basal cell carcinoma

Dosage: CAPSULE

More Information on Dosage

ERIVEDGE family patents

Family Patents

5. Exxua patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7538116 FABRE KRAMER Treatment of sexual disorders
Sep, 2025

(6 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2028

Drugs and Companies using GEPIRONE HYDROCHLORIDE ingredient

NCE-1 date: 23 September, 2027

Market Authorisation Date: 22 September, 2023

Treatment: Treatment of subjects with major depression with sexual dysfunction caused by either major depression or prior treatments, or treatment of subjects with major depression without the risk of sexual dys...

Dosage: TABLET, EXTENDED RELEASE

More Information on Dosage

EXXUA family patents

Family Patents

6. Genosyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11554241 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US9956373 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US8609028 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US8226916 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US10124142 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US11383059 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US11291793 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US8821801 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)

US9522249 VERO BIOTECH INC Conversion of nitrogen dioxide (NO2) to nitric oxide (NO)
Aug, 2025

(21 days ago)




Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: A method of delivering nitric oxide to a patient

Dosage: GAS

More Information on Dosage

GENOSYL family patents

Family Patents

7. Givlaari patent expiration

GIVLAARI IPR and PTAB Proceedings
Can you believe GIVLAARI received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9150605 ALNYLAM PHARMS INC Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
Aug, 2025

(11 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2024
Orphan Drug Exclusivity(ODE-273) Nov 20, 2026

Drugs and Companies using GIVOSIRAN SODIUM ingredient

NCE-1 date: 21 November, 2023

Market Authorisation Date: 20 November, 2019

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

GIVLAARI family patents

Family Patents

8. Mirvaso patent expiration

MIRVASO's oppositions filed in EPO
MIRVASO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(14 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 23, 2016

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL

How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage

MIRVASO family patents

Family Patents

9. Ogsiveo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7342118 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(21 days ago)

US7795447 SPRINGWORKS Imidazole compounds for the treatment of neurodegenerative disorders
Aug, 2025

(21 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 27, 2028
ODE*(ODE*) Nov 27, 2030
Orphan Drug Exclusivity(ODE-452) Nov 27, 2030

Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient

NCE-1 date: 28 November, 2027

Market Authorisation Date: 27 November, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

OGSIVEO family patents

Family Patents

10. Olux E patent expiration

OLUX E's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 PHARMOBEDIENT Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 days ago)




Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 12 January, 2007

Treatment: Treatment of corticosteroid-responsive dermatoses

Dosage: AEROSOL, FOAM

How can I launch a generic of OLUX E before it's drug patent expiration?
More Information on Dosage

OLUX E family patents

Family Patents

11. Omeprazole patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023391 DEXCEL PHARMA Stable benzimidazole formulation
Aug, 2025

(23 days ago)




Drugs and Companies using OMEPRAZOLE ingredient

Market Authorisation Date: 04 December, 2007

Treatment: NA

Dosage: TABLET, DELAYED RELEASE

More Information on Dosage

OMEPRAZOLE family patents

Family Patents

12. Onzetra Xsail patent expiration

ONZETRA XSAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7975690 CURRAX Nasal devices
Aug, 2025

(21 days ago)




Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity

Dosage: POWDER

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents

13. Ozempic patent expiration

What is Ozempic?

Ozempic (semaglutide) is an injectable medication used to improve blood sugar levels in adults with type 2 diabetes. It belongs to a class of drugs called GLP-1 receptor agonists and works by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Ozempic slows digestion and decreases appetite, leading to improved glycemic control and potential weight loss benefits.

What is the Ozempic controversy?

The injectable diabetes medication Ozempic (semaglutide) has recently seen its FDA-approved label updated to warn of potential serious intestinal side effects like obstruction or blockage. The newly added FDA warning highlights that Ozempic may cause severe gastrointestinal issues like intestinal obstruction, intense abdominal pain, vomiting, constipation, and abdominal swelling.

OZEMPIC's oppositions filed in EPO
OZEMPIC IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 05, 2022
New Indication(I-822) Jan 16, 2023
New Dosing Schedule(D-185) Mar 28, 2025
New Indication(I-961) Jan 28, 2028

Drugs and Companies using SEMAGLUTIDE ingredient

NCE-1 date: 05 December, 2021

Market Authorisation Date: 06 October, 2022

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of OZEMPIC before it's drug patent expiration?
More Information on Dosage

OZEMPIC family patents

Family Patents

14. Pradaxa patent expiration

PRADAXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(a day ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 19, 2015
New Indication(I-682) Apr 04, 2017
New Indication(I-683) Apr 04, 2017
M(M-168) Nov 20, 2018
New Strength(NS) Nov 20, 2018
New Indication(I-862) Jun 21, 2024
New Product(NP) Jun 21, 2024
Pediatric Exclusivity(PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

NCE-1 date: 22 December, 2023

Market Authorisation Date: 19 October, 2010

Treatment: NA

Dosage: CAPSULE; PELLETS

How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage

PRADAXA family patents

Family Patents

15. Qoliana patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ Topical brimonidine tartrate formulations that lack chlorine dioxide
Aug, 2025

(20 days ago)




Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS

More Information on Dosage

QOLIANA family patents

Family Patents

16. Qutenza patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10034841 AVERITAS Transdermal therapeutic system comprising an adhesive layer method for siliconizing the back layer of the system and use of said back layer
Sep, 2025

(2 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2014
Orphan Drug Exclusivity(ODE) Nov 16, 2016
New Indication(I-838) Jul 17, 2023

Drugs and Companies using CAPSAICIN ingredient

NCE-1 date: 16 November, 2013

Market Authorisation Date: 16 November, 2009

Treatment: NA

Dosage: PATCH

More Information on Dosage

QUTENZA family patents

Family Patents

17. Saxenda patent expiration

SAXENDA's oppositions filed in EPO
SAXENDA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
New Product(NP) Jan 25, 2017
New Patient Population(NPP) Dec 04, 2023

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 25 January, 2014

Market Authorisation Date: 23 December, 2014

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of SAXENDA before it's drug patent expiration?
More Information on Dosage

SAXENDA family patents

Family Patents

18. Tyvaso Dpi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130685 UNITED THERAP Diketopiperazine salts for drug delivery and related methods
Aug, 2025

(16 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 23, 2025

Drugs and Companies using TREPROSTINIL ingredient

Market Authorisation Date: 23 May, 2022

Treatment: NA

Dosage: POWDER

More Information on Dosage

TYVASO DPI family patents

Family Patents

19. Veltin patent expiration

VELTIN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 days ago)




Drugs and Companies using CLINDAMYCIN PHOSPHATE; TRETINOIN ingredient

Market Authorisation Date: 16 July, 2010

Treatment: Treatment of atopic dermatitis

Dosage: GEL

More Information on Dosage

VELTIN family patents

Family Patents

20. Verdeso patent expiration

VERDESO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 days ago)

US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions
Aug, 2025

(8 days ago)




Drugs and Companies using DESONIDE ingredient

Market Authorisation Date: 19 September, 2006

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM

More Information on Dosage

VERDESO family patents

Family Patents

21. Victoza patent expiration

VICTOZA's oppositions filed in EPO
VICTOZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114833 NOVO NORDISK INC Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(26 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 25, 2015
M(M-115) Apr 06, 2015
M(M-176) Apr 22, 2019
New Indication(I-750) Aug 25, 2020
New Patient Population(NPP) Jun 17, 2022
Pediatric Exclusivity(PED) Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE ingredient

NCE-1 date: 17 December, 2021

Market Authorisation Date: 25 January, 2010

Treatment: NA

Dosage: SOLUTION

How can I launch a generic of VICTOZA before it's drug patent expiration?
More Information on Dosage

VICTOZA family patents

Family Patents

22. Vizamyl patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7270800 GE HEALTHCARE Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
Sep, 2025

(5 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 25, 2018

Drugs and Companies using FLUTEMETAMOL F-18 ingredient

NCE-1 date: 25 October, 2017

Market Authorisation Date: 25 October, 2013

Treatment: Diagnostic radioimaging

Dosage: INJECTABLE

More Information on Dosage

VIZAMYL family patents

Family Patents

23. Xalkori patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7230098 PF PRISM CV Aminoheteroaryl compounds as protein kinase inhibitors
Aug, 2025

(13 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 26, 2016
Orphan Drug Exclusivity(ODE) Aug 26, 2018
Orphan Drug Exclusivity(ODE-15) Aug 26, 2018
M(M-163) Sep 14, 2018
Orphan Drug Exclusivity(ODE-111) Mar 11, 2023
New Indication(I-852) Jan 14, 2024
New Indication(I-897) Jul 14, 2025
Orphan Drug Exclusivity(ODE-328) Jan 14, 2028
Orphan Drug Exclusivity(ODE-407) Jul 14, 2029

Drugs and Companies using CRIZOTINIB ingredient

Market Authorisation Date: 07 September, 2023

Treatment: NA

Dosage: CAPSULE, PELLETS; CAPSULE

More Information on Dosage

XALKORI family patents

Family Patents

24. Zurampic patent expiration

Can you believe ZURAMPIC received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8003681 IRONWOOD PHARMS INC 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester
Aug, 2025

(14 days ago)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2020

Drugs and Companies using LESINURAD ingredient

NCE-1 date: 23 December, 2019

Market Authorisation Date: 22 December, 2015

Treatment: NA

Dosage: TABLET

More Information on Dosage

ZURAMPIC family patents

Family Patents